RY 171.23 -1.0746% SHOP 170.14 2.1432% TD 81.85 -0.7879% ENB 62.92 0.5594% BN 84.78 -1.8636% TRI 244.07 -0.9215% CNQ 44.44 1.6236% CP 111.16 2.0753% CNR 147.09 2.2595% BMO 140.35 -1.2315% BNS 72.0 -0.0971% CSU 4795.7002 -0.5041% CM 88.52 1.351% MFC 42.53 -0.3047% ATD 76.2 1.3163% NGT 62.42 -0.5893% TRP 66.63 1.0005% SU 55.02 0.5299% WCN 269.74 -1.0927% L 182.96 1.4416%
Last update at 2025-02-04T18:56:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -44.30600M | -22.84800M | -81.63700M | -40.43800M | -28.67900M |
| Minority interest | -0.11600M | -0.87200M | -0.47100M | 2.50M | 4.02M |
| Net income | -43.58400M | -22.14100M | -82.81800M | -42.29500M | -28.72600M |
| Selling general administrative | 49.62M | 45.94M | 57.88M | 47.50M | 8.83M |
| Selling and marketing expenses | 40.28M | 37.44M | 26.20M | 41.41M | 18.20M |
| Gross profit | 65.97M | 74.09M | 51.39M | 76.65M | 9.51M |
| Reconciled depreciation | 4.46M | 4.85M | 4.80M | 2.04M | 0.81M |
| Ebit | -34.87600M | -22.39600M | -45.25200M | -22.32700M | -27.26800M |
| Ebitda | -30.41300M | -17.54200M | -40.44800M | -20.28700M | -26.45500M |
| Depreciation and amortization | 4.46M | 4.85M | 4.80M | 2.04M | 0.81M |
| Non operating income net other | - | - | -5.39600M | - | - |
| Operating income | -34.87600M | -17.54200M | -40.44800M | -20.28700M | -25.90600M |
| Other operating expenses | 134.37M | 123.16M | 118.46M | 130.69M | 47.86M |
| Interest expense | 4.56M | 4.96M | 8.34M | 7.55M | 2.22M |
| Tax provision | -0.72200M | -0.70700M | 1.18M | 1.86M | 0.05M |
| Interest income | - | - | - | 10.46M | 2.22M |
| Net interest income | -4.56100M | -4.95500M | -8.34300M | -7.84600M | -2.22400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | 27.45M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.72200M | -0.70700M | 1.18M | 1.86M | 0.05M |
| Total revenue | 99.50M | 105.62M | 78.01M | 110.41M | 21.96M |
| Total operating expenses | 100.85M | 91.64M | 91.84M | 96.94M | 35.41M |
| Cost of revenue | 33.53M | 31.53M | 26.62M | 33.75M | 12.45M |
| Total other income expense net | -9.43000M | -5.30600M | -41.18900M | -20.15100M | -0.54900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -43.58400M | -22.14100M | -82.81800M | -42.29500M | -28.72600M |
| Net income applicable to common shares | - | -23.01300M | -85.27000M | -40.61900M | -14.95900M |
| Preferred stock and other adjustments | - | - | 3.56M | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 93.65M | 125.38M | 153.87M | 160.53M | 191.13M |
| Intangible assets | 8.45M | 11.92M | 15.39M | 18.86M | 22.34M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.80M | 3.70M | 3.76M | 5.67M | 3.10M |
| Total liab | 107.10M | 116.64M | 112.27M | 116.76M | 114.45M |
| Total stockholder equity | -14.01900M | 8.09M | 40.94M | 44.23M | 74.18M |
| Deferred long term liab | - | - | - | 0.81M | - |
| Other current liab | 13.83M | 17.86M | 21.05M | 22.49M | 24.55M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.02M |
| Capital stock | - | 0.03M | 0.03M | 0.03M | 0.02M |
| Retained earnings | -261.90300M | -224.10500M | -180.40500M | -157.39200M | -75.68600M |
| Other liab | - | - | 3.73M | 4.65M | 5.05M |
| Good will | - | - | - | 0.00000M | 27.45M |
| Other assets | 0.00000M | - | 28.81M | 22.72M | 36.99M |
| Cash | 5.40M | 11.57M | 30.88M | 34.30M | 15.67M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 31.16M | 39.59M | 31.21M | 32.52M | 48.17M |
| Current deferred revenue | 2.54M | 4.16M | 4.71M | 3.70M | 6.44M |
| Net debt | 74.30M | 72.20M | 46.99M | 45.30M | 53.35M |
| Short term debt | 5.75M | 9.54M | 0.54M | - | 7.79M |
| Short long term debt | - | 7.74M | 0.54M | - | 7.79M |
| Short long term debt total | 79.70M | 83.77M | 77.87M | 79.60M | 69.02M |
| Other stockholder equity | 247.85M | 232.17M | 221.32M | 201.60M | 149.84M |
| Property plant equipment | - | - | 2.67M | 3.54M | 4.65M |
| Total current assets | 66.44M | 84.01M | 106.99M | 115.40M | 99.70M |
| Long term investments | - | - | - | 21.83M | - |
| Net tangible assets | - | - | 25.55M | 25.37M | 24.39M |
| Short term investments | - | - | - | - | - |
| Net receivables | 30.57M | 37.26M | 46.92M | 52.76M | 58.98M |
| Long term debt | - | 70.00M | 77.33M | 79.60M | 61.23M |
| Inventory | 28.68M | 23.91M | 20.54M | 17.76M | 18.84M |
| Accounts payable | 9.04M | 8.03M | 4.91M | 6.32M | 9.40M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | -0.47100M | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | -8.71100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.03M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -157.39200M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.57M | 20.79M | 28.53M | 0.69M | 0.71M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 27.21M | 41.37M | 46.87M | 45.12M | 91.42M |
| Capital lease obligations | - | 6.03M | - | - | - |
| Long term debt total | - | - | - | 75.49M | 61.23M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.33600M | -0.55200M | -2.39200M | 6.38M | -1.00600M |
| Change to liabilities | 0.00000M | -1.10400M | -4.87400M | -5.94600M | 5.10M |
| Total cashflows from investing activities | - | -0.55200M | -2.39200M | 6.38M | -8.65700M |
| Net borrowings | - | -0.73800M | 2.65M | 48.99M | 19.85M |
| Total cash from financing activities | 8.01M | 16.82M | 49.67M | 42.20M | 22.24M |
| Change to operating activities | - | 0.66M | -1.92000M | 7.77M | 4.43M |
| Net income | -43.58400M | -22.14100M | -82.81800M | -42.29500M | -28.72600M |
| Change in cash | -19.30700M | -3.50400M | 18.63M | 8.99M | -7.44000M |
| Begin period cash flow | 30.88M | 34.38M | 15.75M | 6.76M | 23.64M |
| End period cash flow | 11.57M | 30.88M | 34.38M | 15.75M | 16.20M |
| Total cash from operating activities | -26.98000M | -19.77100M | -28.65000M | -39.59500M | -28.69900M |
| Issuance of capital stock | 8.65M | 16.74M | 49.16M | 0.00000M | 15.56M |
| Depreciation | 4.46M | 4.85M | 4.80M | 2.04M | 0.81M |
| Other cashflows from investing activities | - | - | -2.10100M | 7.51M | - |
| Dividends paid | - | 0.29M | -3.56400M | - | - |
| Change to inventory | -5.78300M | -4.26100M | -1.02000M | 6.43M | -2.76100M |
| Change to account receivables | 9.86M | -0.86900M | 0.09M | -21.09300M | -4.47800M |
| Sale purchase of stock | - | - | 3.56M | 0.35M | 15.95M |
| Other cashflows from financing activities | -0.10100M | 0.82M | 44.16M | 66.70M | 19.98M |
| Change to netincome | - | 3.54M | 55.97M | 11.82M | 14.81M |
| Capital expenditures | 0.34M | 0.51M | 0.29M | 1.12M | 1.01M |
| Change receivables | - | - | 0.09M | - | - |
| Cash flows other operating | - | - | -4.04800M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 18.63M | - | - |
| Change in working capital | 0.42M | -5.15100M | -7.72100M | -12.84100M | -3.87300M |
| Stock based compensation | 2.10M | 2.07M | 2.14M | 2.16M | 0.67M |
| Other non cash items | 10.33M | 0.76M | 55.38M | 12.47M | 0.47M |
| Free cash flow | -27.31600M | -20.28300M | -28.94100M | -40.71800M | -29.70500M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VERO Venus Concept Inc |
0.0003 0.09% | 0.34 | - | - | 0.06 | 1.42 | 1.03 | -3.0103 |
| ABT Abbott Laboratories |
-0.595 0.46% | 127.86 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
0.50 0.13% | 391.64 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.015 0.02% | 90.52 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.05 0.05% | 103.12 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
235 Yorkland Boulevard, Toronto, ON, Canada, M2J 4Y8
| Name | Title | Year Born |
|---|---|---|
| Mr. Domenic Della Penna | Chief Financial Officer | 1962 |
| Mr. Soren Maor Sinay | Chief Operating Officer | 1971 |
| Mr. Rajiv Kanishka Liyanaarchchie De Silva | CEO & Director | 1967 |
| Dr. Hemanth Jacob Varghese CFA, Ph.D. | Pres & Chief Bus. Officer | 1976 |
| Dr. Yoni Iger | VP of Scientific & Clinical Affairs | 1960 |
| Mr. Michael Mandarello | Gen. Counsel & Corp. Sec. | 1985 |
| Mr. Ross J. Portaro | Pres of Global Sales | 1963 |
| Ms. Anat Kotler | VP of Global Marketing & Product Management | 1984 |
| Ms. Anna Georgiadis | VP of Global HR | 1971 |
| Mr. Kenji Shimizu | Interim Chief Innovation Officer | 1953 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...